You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm plans to use the $13.3 million in net proceeds to fund ongoing operations, expansions of its liquid biopsy business, and to service its indebtedness.
The company plans to use proceeds to support its ongoing operations, expansion of its business, and to service existing debts.
The company said it anticipates using net proceeds for working capital and general corporate purposes.
The firm is offering 12.1 million shares of its common stock at a price to the public of $2.90 per share, for expected gross proceeds of $35.1 million.
Net proceeds from the offering of more than 4.9 million shares will be used for working capital and other general corporate purposes.
The offering was a follow-on to a capital raise during the summer that brought in $6 million. The company's CEO said the additional financing was needed to execute on its business plan.
The firm raised €4.7 million through a conditional placement, and €5.0 million through an unconditional direct subscription.
The firm, which said last week it expected to raise $15.9 million, has said it will use the net proceeds for working capital and general corporate purposes.
The company said it plans to use the net proceeds for working capital and general corporate purposes.
The offer of $402 per share was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday.